Definitive Contract HHSN268201200083C
Award Date
9/26/12
Potential Completion Date
12/27/13
Potential Value
$200K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Cellectis Bioresearch Inc.
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed price contract was awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. for the maintenance, repair, and rebuilding of instruments and laboratory equipment. The contract has a ceiling value of $166,880.00 and a completion date of December 8, 2012. There was no set-aside designation for this award. Through this contract, Illumina has provided a range of goods and services to support genomic...
This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. to provide FastTrack genetic analysis services to the NHLBI Division of Intramural Research (DIR) for a one-year period of performance. The total ceiling value of the contract is $309,499.00. Illumina, a manufacturer of sequencing and genomic analysis instruments and reagents, has previously provided similar...
This is a purchase order awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the Department of Health and Human Services, to Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific. The $24,987.48 firm fixed-price contract is for the delivery of AMPLISEQ HD sequenced sites that are predicted to be off-target sites of CRISPR, as part of a study being conducted by The Dunbar Lab. The contract does not have a set-aside designation. Life...
This is a $96,000 firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the National Institutes of Health (NIH), to Cellecta, Inc., a for-profit manufacturer of genetic research tools. The award supports NCATS' RNAi screening facility by enabling the development of flexible functional genomics platforms that offer complementary and orthogonal CRISPR screens to NIH intramural investigators. The contract does not...
This is a $545,400.00 definitive contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract has a firm fixed price pricing type and an ultimate completion date of February 28, 2013. The contract does not have a set-aside designation. Illumina has previously been awarded prime federal contracts and subcontracts by other...
The National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. government, awarded a $229,104 firm fixed-price purchase order contract to Psomagen Inc., a for-profit organization and manufacturer of goods. The contract, which has no set-aside designation, is for investigating transthyretin (TTR) variants and their impact on sickle cell disease severity using Olink proteomics technology. This contract is part of a larger $500 million single-award Indefinite Delivery...
This is a $12,560.96 firm fixed price purchase order awarded to Life Technologies Corporation, a manufacturer of scientific instruments, reagents, and consumables, by the National Heart Lung and Blood Institute (NHLBI) on March 31, 2025. The contract supports the NHLBI lab's requirement for antibodies and cell culture media to assess antigens on the surface within human neutrophils by flow cytometry, and has a completion date of July 1, 2025. The award is not associated with a set-aside program....
This is a delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), a civilian agency. The contract was awarded to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, for the procurement of Illumina kits and reagents to support next-generation sequencing activities at the NHLBI Sequencing Core Facility. The contract has a ceiling value of $25,696.80 and a period of performance...
This is a firm fixed price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Illumina, Inc. The contract has a ceiling value of $81,254.25 and a period of performance ending on August 18, 2017. It does not have a set-aside designation. The contract provides for Illumina to deliver a range of genomic sequencing systems, reagents, consumables, and support services to the NHLBI. This includes Illumina's...
This is a firm fixed price delivery order contract awarded by the National Heart, Lung, and Blood Institute (NHLBI) to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The purpose of the contract is to provide Illumina kits and reagents to support next-generation sequencing on Illumina instruments for NHLBI's Sequencing Core Facility. The contract has a ceiling value of $91,959.00 and a period of performance through September 2, 2025. This contract was not set aside for...